BriaCell Reports New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

On November 30, 2023, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”) a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, was thrilled to announce a new “remarkable responder” in Phase 2 study of the Bria-IMT™ combination regimen. BriaCell’s clinical team reported a patient with extensive metastatic breast cancer who had failed all available therapies. The patient had cancer behind the eye, causing proptosis (eye-bulging) and significant pain that were both resolved with BriaCell’s treatment. Additional survival updates and clinical data sets on the entire Phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium on December 6th and 7th, 2023.

Login Or Register To Read Full Story